Stock Stories - Bamboo Works - China stock insights for global investors

Stories About 2616.HK

WuXi AppTec does health

BRIEF: CStone raises $134 million in share placement at 7% discount

2026-04-15

The share price fell nearly 40% in a week after this drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks.

Stock disconnect triggers investor exodus from CStone Pharma

2024-03-14

CStone Pharmaceuticals announced Wednesday that it has entered into a strategic partnership and exclusive licensing agreement with Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc., for anti-PD-1 antibody Nofazinlimab in mainland China.

FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China

2023-11-02

CStone Pharmaceuticals on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million worth of the company’s shares in the open market over the next six months.

FAST NEWS: CStone says CEO to boost company holdings

2023-10-04

FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer

2023-06-27

CStone breaks up with drugs partner as U.S. rollout stalls

2023-05-18

Discover hidden China stock gems in our weekly newsletter

Follow us

Subscribe to Our Free eNewsletter

Check out our content with some of our syndication partners